Evidence-based review and clinical practice recommendations for the diagnosis and management of common oral mucosal lesions

Abstract

Oral mucosal lesions are a common but diagnostically complex clinical challenge in general dental practice, comprising conditions from benign ulcers to potentially malignant disorders and systemic presentations. Early diagnosis and evidence-based management are crucial to prevent complications, including malignant changes. This review provided a practical protocol for the diagnosis and management of oral mucosal lesions for general dental practitioners. Drawing from National Health Service guidelines and retrieved literature via PubMed and Scopus, the findings were synthesized into structured clinical tables outlining diagnostic pathways, first-line and escalated treatment options, and referral criteria. The framework enables classification by clinical appearance and anatomical site, integrating pharmacological therapies with validated herbal agents such as Nigella sativa, honey, chamomile, and Aloe vera for their mucosal healing properties. An emphasis was placed on differentiating clinically similar conditions and addressing neuropathic disorders like burning mouth syndrome with agents such as amitriptyline. The current review advocated for an evidence-based, stepwise approach that enhances diagnostic accuracy, optimizes treatment outcomes, and aids safe, timely referrals in the management of oral mucosal lesions.

Core Tip: This minireview provided general dental practitioners with a practical, evidence-based guide for the diagnosis and management of common oral mucosal lesions. It introduced a clinical classification framework based on lesion appearance, site, and risk, together with evidence-based first-line and adjunctive treatment options. Diagnostic pathways, severity-based escalation protocols, and integrative herbal therapies were also outlined. By integrating conventional and validated complementary therapies into a single decision-support framework, this minireview aimed to enhance diagnostic accuracy, support safe and effective management, and bridge conventional and integrative strategies in the care of patients with oral mucosal lesions.

INTRODUCTION

Oral mucosal lesions involve a wide range of conditions, including benign lesions, reactive lesions, immune-mediated diseases, and potentially malignant disorders[1,2]. The diagnosis and management of oral lesions present a continuing clinical challenge in general dental practice. This is mainly due to overlapping presentations, variations in severity, and a lack of structured treatment protocols[3,4]. In the United Kingdom the incidence of oral white lesions such as leukoplakia and oral lichen planus is substantial, largely among adults aged 40 years and above with risk factors including tobacco use, alcohol consumption, and systemic immunosuppression[1,5,6]. Moreover, ulcers, candidiasis, and burning mouth syndrome (BMS) are among the most frequently encountered oral lesions, yet their diverse etiologies often complicate early diagnosis and intervention[7,8].

While hospital-based oral medicine departments offer advanced management, the vast majority of patients first present to general dental practitioners (GDPs), highlighting the need for a simplified yet evidence-based diagnostic and therapeutic protocol[9,10]. Several United Kingdom clinical guidelines, including those from the British National Formulary (BNF), National Institute for Health and Care Excellence (NICE), and Public Health England, offer isolated treatment recommendations, but no single, integrated protocol currently exists to guide GDPs through assessment, diagnosis, and treatment escalation[11,12].

This review attempted to bridge this gap by synthesizing evidence from a wide range of peer-reviewed literature and United Kingdom clinical guidelines to create a comprehensive clinical ladder for the treatment of common oral mucosal lesions. It provided structured classification tables and pharmacologic and herbal therapies and implemented an escalation management approach based on severity of the condition. This unified protocol was designed to support GDPs in making informed, stepwise decisions regarding oral lesion care, ultimately improving diagnostic accuracy, treatment outcomes, and timely referrals[11-15].

METHODOLOGY

This evidence-informed narrative review was conducted to develop a comprehensive, clinically applicable protocol for the diagnosis and management of common oral mucosal lesions in general dental practice. A narrative synthesis approach was employed to integrate diverse evidence types, including clinical guidelines, randomized controlled trials (RCTs), systematic reviews, and observational studies, across a range of oral mucosal conditions, populations, and care settings. This flexible approach allowed the incorporation of research evidence, clinical reviews, and clinical guidelines relevant to primary dental care.

Literature search strategy

A targeted and exploratory literature search was performed across major biomedical databases, including PubMed, Scopus, and Web of Science (ISI-indexed journals), covering January 2014 to June 2025. Endorsed clinical guidelines, including the BNF[12] and the NICE[13], were also incorporated.

Search terms were derived from the main diagnostic and management categories represented in the clinical summary tables (Tables 1, 2, 3, 4, and 5). Core keywords and Boolean combinations included: Conditions: “Oral mucosal lesions” OR “oral ulceration” OR “leukoplakia” OR “erythroplakia” OR “oral lichen planus” OR “oral candidiasis” OR “traumatic ulcer” OR ‘burning mouth syndrome” OR “geographic tongue” OR “xerostomia”. Combined with: “Diagnosis” OR “management” OR “treatment’ OR “clinical protocol” OR “general dental practice” OR “guidelines” OR “evidence-based dentistry.”

Table 1.

Clinical classification of common oral mucosal lesions based on appearance, site, and risk profile

Lesion type	Common sites	Typical appearance	Differential diagnosis	Risk groups	Initial diagnostic approach	Ref.
Leukoplakia	Buccal mucosa, tongue, floor of mouth	White plaque, non-removable, asymptomatic	Frictional keratosis, oral lichen planus, candidiasis	Smokers or tobacco chewing users, the elderly, and alcohol users	Clinical exam + biopsy mandatory to determine the degree of dysplasia	[1,16-18]
Oral lichen planus	Buccal mucosa, gingiva, tongue	White striae (Wickham’s), erythematous, or erosive lesions	Lupus, leukoplakia, lichenoid drug reaction	Middle-aged adults, females > males	Clinical history + biopsy with immunofluorescence	[1,5,27,28,31]
Erythroplakia	Floor of the mouth, soft palate, tongue	Red, velvety lesion, well-demarcated	Inflammation, trauma, erosive lichen planus	Tobacco/alcohol users, the elderly	Urgent biopsy (90% show dysplasia or carcinoma)	[2,6,18,20]
Traumatic ulcer	Anywhere in occlusal or prosthetic trauma zones	Painful ulcer with red halo, irregular margins	Aphthous ulcer, SCC, syphilitic chancre	All age groups, especially denture wearers	History + remove cause; reassess in 2 weeks	[1,13,19,26]
Oral candidiasis, including angular cheilitis	Tongue, palate, buccal mucosa, oral commissures	White patches that can be wiped off, red areas, burning sensation, fissures at the oral commissures (angular cheilitis)	Leukoplakia, lichen planus, geographic tongue	Immunocompromised, denture users, diabetics	Swab for culture; response to antifungals such as nystatin (Nystan®) confirms diagnosis	[1,2,8,24]

SCC: Squamous cell carcinoma.

Table 2.

Evidence-based first-line treatments and adjunct therapies for common oral mucosal conditions

Condition	First-line treatment	Dosage and frequency	Treatment duration	Adjunct therapy	Ref.	Evidence level (GRADE)
Aphthous ulcers	Betamethasone sodium phosphate 0.5 mg tablets dissolved in water (Betnesol® mouthwash)	Rinse 4 times/day QID	7-10 days or until complete symptom resolution; reassess at 10 days if persistent	Chlorhexidine gluconate 0.2% (Corsodyl®), Benzydamine hydrochloride 0.15% (Difflam®), topical lidocaine (Acuvisc®)	[1,12-15]	A
Oral lichen planus	Clobetasol propionate 0.05% ointment (Dermovate®). If not working: Tacrolimus 0.03% ointment (Protopic®)1	Apply a thin layer BID after meals. Apply 4 times daily	2-4 weeks, then mandatory reassessment; discontinue if no improvement after 4 weeks	Benzydamine hydrochloride 0.15% (Difflam®), nystatin suspension if fungal co-infection	[1,12-15]	A
Oral candidiasis including (angular cheilitis)	Nystatin oral suspension 100000 units/mL (Nystan®) or miconazole 2% oral gel (Daktarin®)	1 mL QID (hold in mouth, then swallow; dietary support)	7-14 days; continue 48 hours after clinical resolution; reassess at day 16 if ongoing	Vitamin B12 or iron supplementation; because nutritional deficiencies (iron, vitamin B12) provoke Candida albicans infection	[1,12-15]	A
Traumatic ulcers	Remove traumatic source (e.g., denture adjustment)	NA	Reassess at 10-14 days; biopsy if not fully healed by day 14	Lidocaine 2% gel (Acuvisc®), Chlorhexidine gluconate (Corsodyl®), Benzydamine hydrochloride (Difflam®)	[1,12-15]	A
Herpetic stomatitis	Aciclovir 200 mg tablets	Five times daily for 5 days	Complete 5-day course; review at day 7 if lesions persist	Benzydamine hydrochloride rinse (Difflam®), hydration, analgesics	[1,12-15]	A

¹Off-label use on oral mucosa; specialist initiation recommended. Evidence level (GRADE): A: High; B: Moderate; C: Low. BID: Twice a day; QID: Four times a day; NA: Not available.

Table 3.

Systemic and adjunctive oral conditions: Diagnostic pathways and medical management

Condition	Diagnostic approach	First-line treatment	Dosage and frequency	Follow-up plan	Ref.	Evidence level (GRADE)
Oral candidiasis, including angular cheilitis	Oral swab for culture, assess risk factors (e.g., dentures, diabetes)	Nystatin oral suspension 100000 units/mL (Nystan®) or miconazole 2% oral gel (Daktarin®)	1 mL QID (hold in mouth then swallow)	Continue 48 h after resolution; reassess if unresponsive	[12-15]	A
Burning mouth syndrome (stage 1)	Swab to rule out Candida; blood test for vitamin B12, ferritin, folic acid	Correct underlying deficiency: Ferrous fumarate 200 mg (Fersaday®), Cyanocobalamin 1 mg (Cytacon®), folic acid 5 mg	Iron TID; vitamin B12 daily; folic acid daily	Repeat blood work in 3-4 weeks; escalate to stage 2 if unresolved	[12-15]	A
Burning mouth syndrome (stage 2)	Diagnosis of exclusion	Amitriptyline hydrochloride (generic)1; titrate cautiously	10-25 mg nocte; titrate slowly over 2-4 weeks	Review every 2-4 weeks; refer if no response by 8 weeks	[12-15]	A
Geographic tongue (migrating glossitis)	Clinical diagnosis: Assess for fungal co-infection	Miconazole 2% + hydrocortisone 1% cream (Daktacort®)	Apply BID for up to 7 days	Stop after 7 days or symptom relief; review at 2 weeks	[12-15]	A
Xerostomia	Medication history, salivary flow rate	Artificial saliva (Glandosane®) or Pilocarpine hydrochloride	Pilocarpine 5 mg TID (specialist only)	Manage oral hygiene, identify the underlying cause. Review salivary flow at 4 weeks; discontinue if no benefit	[12-15]	A

¹Off-label for neuropathic oral pain. Evidence level (GRADE): A: High; B: Moderate; C: Low. BID: Twice a day; TID: Three times a day; QID: Four times a day; Nocte: At night.

Table 4.

Severity-based escalation protocol for common oral mucosal lesions in general dental practice

Severity level	Clinical indicators	First-Line management	Escalated treatment (if unresponsive)	Referral criteria	Ref.	Evidence level (GRADE)
Mild	Frictional keratosis, traumatic ulcer < 2 weeks, asymptomatic white patches	Oral hygiene, remove irritant, topical analgesics: Lidocaine hydrochloride 2% gel (Acuvisc®), Chlorhexidine gluconate 0.2% (Corsodyl®)	Betamethasone sodium phosphate 0.5 mg (Betnesol®) rinse, Benzydamine hydrochloride 0.15% (Difflam®) rinse	If symptoms persist > 2-3 weeks → reassess and consider biopsy	[1,2,12,19,25]	A
Moderate	Recurrent ulcers, symptomatic oral lichen planus, oral candidiasis	Clobetasol propionate 0.05% ointment (Dermovate®), Nystatin 100000 units/mL (Nystan®), Miconazole 2% oral gel (Daktarin®)	Fluconazole 50-100 mg OD, tacrolimus 0.03% ointment (Protopic®), Amitriptyline 10-25 mg nocte	Unresponsive after 2-4 weeks of compliant treatment → urgent review	[1,8,12,23,24]	A
Severe	Erythroplakia, non-healing ulcer > 3 weeks, severe pain, suspicious lesions	Urgent biopsy, clobetasol propionate (Dermovate®), systemic steroids as indicated	Multidisciplinary review, systemic immunomodulation	Urgent referral for any persistent red or red-white patch (erythroplakia/erythroleukoplakia), non-healing ulcer > 3 weeks, or unexplained lump on lip/oral cavity	[2,12,20,27,28]	A

Evidence level (GRADE): A: High; B: Moderate; C: Low. OD: Once a day; Nocte: At night.

Table 5.

Supportive herbal and traditional remedies for common oral mucosal lesions: Scientific basis and use

Condition	Herbal remedy (scientific name)	Therapeutic action	Recommended use	Evidence/source	Ref.	Evidence level (GRADE)
Aphthous ulcers	Chamomile, honey, alum (shabbah is potassium aluminum sulfate), myrrh	Anti-inflammatory, antimicrobial, astringent, antiseptic	Topical application or rinse 3-4 ×/day for 7-10 days; reassess at day 10	Clinical and traditional studies	[31-35]	A
Oral lichen planus	Aloe vera, Nigella sativa (black seed oil)	Anti-inflammatory, antioxidant, epithelial repair	Apply topically twice daily for 4 weeks; reassess at week 4	RCTs and in vitro studies	[31-35]	A
Burning mouth syndrome	Capsaicin	Neuropathic desensitization	Low-concentration rinse or gel BID for 2 weeks; Review response at 14 days; off-label; use only pharmacy-compounded 0.025%-0.075% formulations	Small-scale clinical trials	[36-40]	B
Oral candidiasis	Tea tree oil	Antifungal, antiseptic	Diluted rinse 2-3 ×/day for 14 days; do not swallow	In vitro and pilot trials	[38-41]	B
General oral health	Curcumin (turmeric)	Anti-inflammatory, antioxidant	Curcumin rinse BID or 500 mg capsules daily for 4-6 weeks	Systematic reviews	[35,37]	A

Evidence level (GRADE): A: High; B: Moderate; C: Low. RCT: Randomized controlled trial; BID: Twice a day.

This approach was not systematic or comprehensive but rather purposeful and integrative and designed to capture clinically relevant evidence and prioritize practical applicability over exhaustive literature retrieval in a general dental context. A total of 47 peer-reviewed and guideline-based sources were included following relevance screening.

Inclusion/exclusion criteria

Studies were included if they were peer-reviewed, English-language publications published between January 2014 and June 2025 and addressed the diagnosis or management of oral mucosal lesions in general dental practice, including clinical guidelines, RCTs, systematic or scoping reviews, narrative reviews, or observational studies. Case reports, non-English publications, animal or in vitro studies, and publications before 2014 were excluded.

Data selection and synthesis and evidence grading

All references were appraised using a simplified GRADE approach: Grade A (high): Consistent findings from ≥ two RCTs, systematic reviews/meta-analyses, or national guidelines; Grade B (moderate): Cohort, cross-sectional, audit, or pre-post intervention studies; and Grade C (low): Narrative reviews, expert consensus, textbooks, or pilot studies.

The selected literature encompassed a broad spectrum of inflammatory, infectious, immune-mediated, traumatic, and potentially malignant oral mucosal conditions. Studies were prioritized based on clinical relevance, diagnostic clarity, and applicability to general dental practice.

Data were extracted, synthesized narratively, and organized into five structured tables summarizing: (1) Clinical classification of oral mucosal lesions by appearance, site, and risk profile (Table 1); (2) First-line and adjunctive treatments (Table 2); (3) Diagnostic pathways (Table 3); (4) Escalation protocols for GDPs (Table 4); and (5) Herbal and traditional remedies with published scientific support (Table 5).

All therapeutic recommendations in Tables 2, 3, 4, and 5 were anchored to current national guidelines[12-15], conferring Grade A certainty for core pharmacological interventions. Off-label uses were designated with risk-benefit language and specialist supervision advice. Dosing regimens, treatment durations, follow-up triggers, and escalation thresholds have been standardized and quantified throughout. Red-flag biopsy criteria were quoted verbatim from NICE NG12[12-15] and integrated into Table 4. Each clinical recommendation in Tables 2, 3, 4, and 5 is annotated with its evidence grade (A-C), enabling readers to assess confidence and certainty in the guidance.

RESULTS

Overall, 47 references were identified and included in this narrative review. The findings were synthesized into a practical clinical framework designed to support GDPs in the diagnosis and management of common oral mucosal lesions. The evidence was organized into five key domains covering lesion classification, treatment modalities, systemic considerations, severity-based management pathways, and complementary therapeutic options and presented across five structured tables that summarize the diagnostic and therapeutic approaches. These results demonstrated the range of oral mucosal conditions encountered in general dental practice and reveal how evidence-based and integrative strategies can be applied in everyday clinical decision making.

Table 1 presents the classification of oral mucosal lesions. It shows a structured diagnostic overview that aids GDPs in differentiating between lesions of traumatic, reactive, infectious, immune-mediated, and potentially malignant origins. Each lesion type is matched with characteristic symptoms and a diagnostic pathway, such as clinical examination, biopsy, or serological testing. For example, leukoplakia, often a white non-removable lesion, requires biopsy due to its premalignant potential[2,16-18]. On the other hand, frictional keratosis typically resolves with the removal of local irritants and does not necessitate histopathological examination. Such stratification allows early detection and timely referral for high-risk cases like erythroplakia or lupus-associated lesions[9,19-21].

Table 2 outlines the therapeutic protocols tailored for specific oral lesions, grounded in United Kingdom clinical practice. It highlights the use of National Health Service (NHS)-approved medications such as Betnesol for aphthous ulcers and Dermovate or Protopic for oral lichen planus[1,12-15]. The table also incorporates appropriate mouthwashes, like Corsodyl and Difflam, for symptom control. Importantly, the inclusion of biopsy guidance for each lesion type ensures that potentially malignant conditions are not missed[2]. The therapeutic recommendations align with evidence-based protocols and offer GDPs a clear framework to manage oral lesions systematically and safely within primary care[1,9,10].

The third table broadens the scope of this review by addressing systemic and secondary conditions that influence the health of the oral mucosa, including oral candidiasis, BMS, geographic tongue, and xerostomia. These conditions often present in conjunction with local or systemic factors, requiring a broader diagnostic approach.

For BMS the recommended management follows a two-phase protocol: Initial evaluation focuses on ruling out fungal infections and nutritional deficiencies. If symptoms persist after exclusion of these factors, treatment shifts toward neuropathic pain modulation using agents such as low-dose amitriptyline[7,15,22-24]. Oral candidiasis is managed with topical antifungals, such as Nystatin and Daktarin, and escalated to systemic fluconazole when necessary[1,8,12]. This layered strategy ensures comprehensive patient care while limiting overtreatment in cases that are self-limiting or nutritional in origin.

Table 4 introduces a practical “ladder” of oral medicine that aligns treatment intensity with lesion severity, providing a rational and auditable escalation pathway for GDPs. Mild conditions, such as frictional keratosis and traumatic ulcers, can be confidently managed in primary care with irritant removal, symptomatic relief, and patient education[1,9,13,25,26]. In contrast, moderate-to-severe cases, including erosive lichen planus, persistent candidiasis, or erythroplakia, require biopsy, potent topical immunosuppressants, and prompt onward referral[20,27,28]. Referral criteria have been explicitly aligned with NICE NG12[13] and RCPath tissue pathways[14]. Red-flag triggers [persistent red or red-white patches (erythroplakia/erythroleukoplakia), non-healing ulcers lasting longer than 3 weeks, and unexplained lumps on the lip or in the oral cavity] mandate urgent specialist assessment within 14 days. Integration of Emery and Vedsted[29] and Grimes et al[30] highlights the evidence-based intent of dentist-first triage while underscoring potential risks, emphasizing the critical importance of safety netting. This Grade A framework remains internationally applicable through the universal 2-week referral principle, irrespective of local pathway variations, and effectively bridges primary and specialist care[13,14].

The inclusion of Table 5 acknowledges the growing interest in evidence-based herbal therapies as supportive treatments. Substances like chamomile, honey, and turmeric have shown anti-inflammatory and antimicrobial properties in clinical studies and are well-suited for minor lesions such as aphthous ulcers[21-23]. Aloe vera and black seed oil have demonstrated benefits in the management of oral lichen planus, offering patients additional options with fewer systemic side effects[31,32]. Importantly, the protocol advises that such remedies are adjunctive and not replacements for pharmacological or surgical interventions, thereby maintaining clinical standards while embracing integrated care where appropriate.

DISCUSSION

This protocol-based review highlighted the importance of a structured, evidence-driven approach for the diagnosis and management of oral mucosal lesions in general dental practice.

The selected lesions encompass a spectrum from common benign conditions, such as aphthous and traumatic ulcers, to immune-mediated disorders like oral lichen planus, and potentially malignant lesions such as leukoplakia and erythroplakia. This scope ensures coverage of the conditions in which misdiagnosis has the most serious consequences. By contrast, salivary gland disorders and craniofacial pain syndromes were excluded as these are less common in GDP practice and often require advanced investigations beyond primary care, such as imaging or immunological testing. Excluding such conditions preserved the practical focus of the review and avoided diluting its clinical applicability.

Overall, this review provided a comprehensive yet practical guide to assist GDPs in navigating the complexity of oral mucosal conditions. The classification system presented in Table 1 simplifies diagnosis by organizing lesions according to their clinical appearance, site, and associated symptoms. This system when combined with targeted first-line therapies grounded in United Kingdom NHS guidelines (Table 2) enables efficient and confident treatment selection[2,4,9]. Moreover, the inclusion of systemic and adjunctive considerations such as hematinic deficiencies, candidal infections, and neuropathic causes (Table 3) expands diagnostic accuracy and encourages a holistic evaluation[12-15]. Escalation of care is guided by the severity-based protocol (Table 4), enabling GDPs to transition confidently from conservative management to immunomodulatory therapy or urgent referral when red-flag features are present[9,10,13]. All high-risk triggers are directly mapped to NICE NG12[13] and RCPath tissue pathways[14] and reinforced by national audits[29,30], ensuring specialist review within 14 days for suspected malignancy. This structured, evidence-informed approach (Grade A) facilitates robust clinical decision-making, minimizes diagnostic delay, reduces uncertainty in primary care, and empowers GDPs to manage the majority of benign and moderate lesions safely and effectively all while maintaining an auditable, medico-legally defensible pathway.

Table 5 introduces scientifically supported herbal treatments as complementary options[31-37], particularly in chronic or refractory lesions, offering both clinical and patient-centered benefits[38-41]. A crucial element in managing mucosal diseases is the accurate differentiation of similar-appearing lesions; for instance, leukoplakia presents as a non-removable white plaque with dysplastic potential requiring biopsy[2,42] while oral lichen planus manifests with characteristic bilateral Wickham striae and often coexists with pain or erythema[1,43]. In contrast, candidiasis though also white is typically removable and responds to antifungal therapy[12,24], serving as a useful diagnostic clue. In persistent aphthous ulcers the use of silver nitrate for chemical cauterization accelerates healing by coagulating proteins, sealing nerve endings, and reducing microbial colonization, offering rapid symptomatic relief[44].

Moreover, low-level laser therapy has demonstrated significant effectiveness in reducing pain and accelerating healing time in recurrent aphthous stomatitis, offering a promising non-pharmacological treatment modality for symptomatic relief[45]. The therapeutic ladder for oral lichen planus typically begins with high-potency topical corticosteroids such as clobetasol propionate 0.05% (Dermovate^®), which suppresses proinflammatory cytokines, and escalates to calcineurin inhibitors like tacrolimus 0.03% (Protopic^®), which blocks T cell activation via interleukin 2 inhibition. Both therapies can be alternated or combined in resistant cases[1,12,46]. Topical adjuncts like chlorhexidine gluconate 0.2% (Corsodyl^®) act as antiseptics, benzydamine hydrochloride 0.15% (Difflam^®) offers analgesia and anti-inflammation, and lidocaine 2% gel (Acuvisc^®) provides mucosal anesthesia. Artificial saliva substitutes such as Glandosane^® are vital in managing xerostomia, especially when due to medications or autoimmune conditions[1,12,15].

In addition to conventional treatments, several herbal therapies have shown promise through mechanisms supported by recent evidence. Nigella sativa (black seed oil) and curcuma longa (turmeric) exhibit potent anti-inflammatory and antioxidant effects[35,37]. Aloe vera, Matricaria chamomilla (chamomile), and Commiphora myrrha (Murrah) promote mucosal repair and symptom relief[31,36,41]. Honey supports wound healing and antimicrobial defense[20]. Tea tree oil combats fungal colonization[33,34]. Capsaicin reduces neuropathic pain through transient receptor potential vanilloid 1 receptor desensitization[39].

In cases of BMS, especially when no local cause is found, systemic evaluation and neuropathic management become central[22,23]. Amitriptyline, a tricyclic antidepressant, plays a key role in managing BMS by modulating pain pathways through serotonin-norepinephrine reuptake inhibition and sodium channel blockade, supporting its use as a second-line agent following exclusion of nutritional deficiencies such as vitamin B12, folic acid, and ferritin[1,12,47]. Taken together, these findings support a clinically rational, patient-centered, and evidence-informed protocol for oral mucosal care in dental settings.

This review presented a practical, evidence-based protocol to support GDPs in the diagnosis and management of common oral mucosal lesions. By integrating clinical classification with pharmacological, adjunctive, and herbal options, the protocol seeks to enhance early detection, ensure timely intervention, and minimize misdiagnosis and unnecessary referrals. Despite its clinical utility several limitations must be acknowledged. The recommendations rest on current NHS guidelines and the best available literature, which remains subject to future evolution. Included studies vary considerably in design, sample size, and population, contributing to heterogeneity that may affect reproducibility. Herbal and supportive therapies, although promising, often rely on preliminary or small-scale trials rather than large, multicenter RCTs, introducing moderate imprecision and potential publication bias. The narrative synthesis approach, while appropriate for this broad, practice-focused review, precludes formal meta-analysis and quantitative pooling of effect sizes. Off-label uses of certain agents lack long-term oral mucosal safety data, and implementation success depends on equitable access to diagnostic tools and laboratory services not uniformly available across dental settings. While the core conventional recommendations align closely with NICE and BNF guidance and carry high certainty, ongoing research is essential to strengthen the evidence base for adjunctive and herbal approaches and to refine integrated management strategies for common oral mucosal lesions.

GDPs are encouraged to adopt a protocol-driven approach for assessing oral lesions and escalating treatment based on severity and response. A biopsy should be considered for non-healing white or red patches. Hematinic screening is recommended in unexplained mucosal conditions. Herbal therapies may be offered as adjuncts, not replacements, to conventional care. Amitriptyline should be reserved for confirmed neuropathic cases of BMS after exclusion of local and systemic causes. Ongoing research and audit are necessary to validate and refine this approach across clinical environments.

CONCLUSION

This minireview offered GDPs a practical, evidence-based protocol for the diagnosis and management of common oral mucosal lesions. While firmly anchored in current guidelines, its recommendations have limitations. Future research and clinical audits are needed to validate and refine these recommendations.